Thermo Fisher Scientific on Thursday morning reported a 19 percent increase in first quarter revenues, driven by growth in most of its business segments.

Pfizer and BioNTech have submitted an application for Emergency Use Authorization for a COVID-19 vaccine booster dose in young children.

Recently, the first 5G digital mobile hospital in China jointly built by Roche Diagnostics, GE Healthcare, Boao Yiling Medical Group and Yutong Group was officially delivered.

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2022 Prix Galien International Awards.

MDxHealth reported after the close of the market Wednesday a 21 percent increase in first quarter 2022 sales.

Qiagen on Tuesday afternoon reported strong first quarter revenues that blew by Wall Street estimates, driven by growth in its molecular diagnostics business.

Exact Sciences reported after the close of the market on Tuesday that its first quarter revenues rose 21 percent year over year.

On April 27, Autobio, BSBE, Easy Diagnosis, Medicalsystem, Dian Diagnostics, Hybribio and Kingmed released 2022 Q1 report.

Wondfo, BGI, Leadman, Sinocare, ACROBiosystems, NanoMicro released 2022 Q1 Report

Illumina said on Monday that it has entered into a collaboration with Germany's Hannover Medical School to implement whole-genome sequencing in critically ill children suspected of having a genetic or rare disease.

Laboratory Corporation of America said Friday that it is collaborating with Getlabs phlebotomy service to provide at-home blood draws and specimen collection.

On April 24, Shanghai Universal Biotech's released its 2021 annual report. The report shows that in 2021, the company will achieve operating income of CNY 1.110 billion, a year-on-year increase of 30.69%.

Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022.

April 25, Swiss drugmaker Roche's (ROG.S) first quarter sales rose a better-than-expected 10% on strong U.S. demand for rapid COVID-19 antigen tests and drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia.

For the three months ending March 31, total revenue was 74,283.49 million CNY compared to 39.53% growth in the year-ago period with the total profit of 35, 813.66 million CNY compared to 76.23% growth over the same period last year.